Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen

Transplantation Proceedings

Volumn 37, Issue 2, 2005, Pages 1211-1213

  Florman, S ^a,b   Alloway, R ^a   Kalayoglu, M ^a   Lake, K ^a   Bak, T ^a   Klein, A ^a   Klintmalm, G ^a   Busque, S ^a   Brandenhagen, D ^a   Lake, J ^a   Wisemandle, K ^a   Fitzsimmons, W ^a   First, M R ^a  

^a TULANE UNIVERSITY   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AREA UNDER THE CURVE; CLINICAL TRIAL; CONFERENCE PAPER; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DIABETES MELLITUS; DRUG DOSE REGIMEN; DRUG RELEASE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EXPERIENCE; FEMALE; GLUCOSE INTOLERANCE; HUMAN; KIDNEY FUNCTION; LABORATORY; LIVER BIOPSY; LIVER FUNCTION; LIVER GRAFT; LIVER GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECIPIENT; STEADY STATE; TREATMENT FAILURE;

EID: 17844396683     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.11.086     Document Type: Conference Paper

References (6)

1. M.R. First, W.E. Fitzsimmons New drugs to improve transplant outcomes Transplantation 77 2004 S88
2. R.H. Didlake, K. Dreyfus, R.H. Kerman Patient non-compliance: a major cause of late graft failure in cyclosporine-treated renal transplants Transplant Proc 20 1998 63
3. J.A. Butler, P. Roderick, M. Mullee Frequency and impact of nonadherence to immunosuppressants after transplantation: a systematic review Transplantation 77 2004 769
4. D.J. Schuirmann A comparison of the two-sided tests procedure and the power approach for assessing the equivalence of average bioavailability J Pharmacokin Biopharm 15 1987 657
5. Guidance for Industry. Bioavailability and bioequivalence studies for orally administered drug products - general considerations. U.S. Department of Health, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), July 2002
6. Guidance for Industry. Bioavailability and bioequivalence studies for orally administered drug products - general considerations. U.S. Department of Health, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), March 2003; BP revision 1